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a  b  s  t  r  a  c  t
A  new  immunologically  distinct  strain  (A-Iran-05)  of  foot-and-mouth  disease  virus  serotype  A  emerged
in  the  Middle  East  in 2003  that  replaced  the  previously  circulating  strains  (A-Iran-96  and  A-Iran-99)  in
the region.  This  resulted  in  introduction  of  a  new  vaccine  of  this  strain  (A/TUR/2006)  in 2006.  Though
this  vaccine  strain  has  been  predominantly  used  to control  FMD  in  the region,  recent  viruses isolated  in
2012  and  2013  have  shown  antigenic  drift and  a  poor  match  with  it.  In this  study,  we  report  the  antigenic
matching  results  and  capsid  sequence  data  of  currently  circulating  viruses  belonging  to the  SIS-10  andeywords:
MD  virus
ntigenic variation
apsid sequence
pitopes
olyclonal antibodies
SIS-12  sub-lineages  of  A-Iran-05  (isolated  in  2012  and  2013),  highlighting  the  inadequacy  of  the  currently
used  serotype  A vaccines.  Implications  of  these  results  in the  context  of FMD  control  in the  Middle  East
are  discussed.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ntigenic determinants
. Introduction
Foot-and-mouth disease (FMD) affects both domestic and wild
loven-hoofed animals and remains a globally important livestock
nimal disease. It has devastating economic implications when-
ver outbreaks occur in disease free countries as in 2001 in the
K and in 2011 in Japan. In developing countries where the dis-
ase is endemic, as well as ongoing direct losses, the export of
ive animals and animal products is compromised. Vaccination
s an important tool for FMD  control. The causative agent, FMD
irus (FMDV) is a single-stranded, positive-sense RNA virus, the
rototype virus of the genus Aphthovirus, family Picornaviridae.  Cur-
ently, six immunologically distinct serotypes (O, A, Asia 1, South
frican Territory 1, 2 and 3), each with multiple subtypes are found
n the world; no outbreaks due to the seventh serotype “C” have
een reported since 2004.
More than 60% of outbreaks worldwide are caused by serotype
, followed by serotype A (http://www.wrlfmd.org). Serotype A
iruses are present on all continents where FMD  is reported,
nd are antigenically diverse with as many as 32 distinct sub-
ypes, often with incomplete cross-protection between them [1].
hree serotypes, O, A and Asia 1 have predominated in the Mid-
le East (ME) in recent years, with incursions of SAT 2 viruses
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.0/).in Bahrain and Palestine in 2012 (http://www.wrlfmd.org), prob-
ably because of trade links with African countries. Serotype O
outbreaks in the region are mainly controlled by O Manisa and
O Pan-Asia 2 vaccines which provide broad-spectrum protection.
However, the situation with serotype A outbreaks is different
because of periodic emergence of antigenically distinct variants,
necessitating development of new vaccine strains, typically every
5–10 years. Following the emergence of the antigenically dis-
tinct A-Iran-05 genotype in the ME,  a new vaccine strain (v/s),
A/TUR/2006 was developed by the FMD  vaccine manufacturing
companies [2] and has been routinely used for FMD  control in
the region successfully since 2006. However, some recent isolates
have exhibited poor cross-reactivity in in vitro serological match-
ing tests, indicating lower expected protection. In a previous study,
we reported the inadequacy of serotype A vaccines against viruses
from the BAR-08 and ARD-07 sub-lineages and identiﬁed surface
exposed capsid amino acid residue differences that could under-
lie the miss-matches [3]. In this study, we report similar studies
with viruses from the SIS-10 and SIS-12 sub-lineages (isolated in
2012 and 2013 from Iran and Turkey) also showing low cross-
reactivity with three post-vaccinal sera, raised against two old
(A22/IRQ/24/64 and A/TUR/2006) and one new (A/IRN/78/2009)
candidate vaccine strain. These results extend our previous ﬁnd-
ings, highlighting the inadequacy of the currently used serotype A
v/s for use in FMD  control programmes in the region and also iden-
tifying further capsid amino acid (aa) residues of likely antigenic
signiﬁcance.
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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. Materials and methods
Cells and viruses: Eighteen serotype A viruses from the ME
ubmitted to the Food and Agriculture Organisation’s World Ref-
rence Laboratory for FMD  (WRLFMD) at Pirbright were used in
his study (Table 1). Two are the v/s A22/IRQ/24/64 (A22/Iraq) and
/TUR/2006 that were originally isolated in Iraq and Turkey, in 1964
nd 2006 respectively; the sixteen other viruses were isolated over
 ﬁve year period between 2009 and 2013 (Table 1). With the excep-
ion of a single isolate of unknown origin, all samples were derived
rom cattle epithelial tissues, and were initially grown in primary
ovine thyroid cells (BTY) with subsequent passage in either BHK-
1 or IB-RS2 cells. Stocks of virus were prepared by infecting IB-RS2
ell monolayers and were stored as clariﬁed tissue culture harvest
aterial at −70 ◦C until required.
Polyclonal serum: Pooled bovine post-vaccination sera (BVS)
aised against A22/Iraq and A/TUR/2006 v/s [3] were used in this
tudy. In addition, BVS were raised against two new ﬁeld isolates,
/IRN/78/2009 isolated from Iran in 2009 (sub-lineage: FAR-09)
nd A/IRN/07/2013 (sub-lineage: SIS-10), essentially as described
arlier (3). These last two isolates do not serologically cross-
eact with either of the established serotype A v/s (A22/Iraq and
/TUR/2006) used in the region. Brieﬂy, ﬁve cattle per v/s were
mmunised with inactivated, puriﬁed 146S FMD  virus particles in
SA-206 adjuvant. Bulk blood was collected on either 21or 28 days
ost-vaccination from the immunised animals for preparation of
era. For each antigen, a pool of sera from ﬁve animals was  used in
he serological tests. The A/IRN/78/2009 and A/IRN/07/2013 anti-
era exhibited equivalent titres (log10 2.39 and 2.25, respectively)
y virus neutralisation test (VNT) using homologous virus.
Two-dimensional micro neutralisation assay (2D-VNT): The 2D-
NT was carried out using pooled post-vaccination sera following
stablished methodology [4]. Antibody titres were calculated
rom regression data as the log10 reciprocal antibody dilution
equired for 50% neutralisation of 100 tissue culture infective
nits of virus (log10 SN50/100 TCID50). The antigenic relationship
f viruses based on their neutralisation by antibodies is given by
he ratio: ‘r1’ = neutralising antibody titre against the heterologous
irus/neutralising antibody titre against the homologous virus. The
igniﬁcance of differences in the values of ‘r1’ obtained by the poly-
lonal antiserum was evaluated according to standard criteria [5].
Nucleotide (nt) sequencing and analysis of the sequence data: The
equences of the entire capsid coding region (P1) of SIS-10 AND 12
iruses were generated in order to compare their deduced amino
able 1
ist of serotype A viruses used in this study. ND: not designated; NK: not known; N/A: n
ccession numbers.
No. Name Topotype Strain Sub-lineage C
1 A22/IRQ/24/64 ASIA A22 ND M
2 A/TUR/2006 ASIA A-Iran-2005 ND E
3 A/IRN/78/2009 ASIA A-Iran-2005 FAR-09 F
4 A/IRN/15/2012 ASIA A-Iran-2005 SIS-12 Z
5  A/IRN/22/2012 ASIA A-Iran-2005 SIS-10 Q
6  A/IRN/24/2012 ASIA A-Iran-2005 SIS-10 T
7  A/IRN/25/2012 ASIA A-Iran-2005 SIS-12 T
8  A/IRN/30/2012 ASIA A-Iran-2005 SIS-12 M
9  A/IRN/32/2012 ASIA A-Iran-2005 SIS-10 Y
10  A/IRN/33/2012 ASIA A-Iran-2005 SIS-12 E
11  A/IRN/35/2012 ASIA A-Iran-2005 SIS-12 Q
12  A/IRN/37/2012a ASIA A-Iran-2005 SIS-10 A
13  A/TUR/05/2012 ASIA A-Iran-2005 SIS-10 C
14  A/IRN/01/2013 ASIA A-Iran-2005 SIS-10 T
15  A/IRN/04/2013 ASIA A-Iran-2005 SIS-10 A
16  A/IRN/06/2013 ASIA A-Iran-2005 SIS-10 E
17  A/IRN/07/2013 ASIA A-Iran-2005 SIS-10 A
18  A/IRN/10/2013a ASIA A-Iran-2005 SIS-10 T
a P1 sequence of these viruses could not be generated in this study. 34 (2016) 3199–3206
acid (aa) compositions. RNA extraction from the cell culture grown
viruses, reverse transcription (RT), polymerase chain reaction (PCR)
and sequencing was  performed as described previously [3]. The
computer analysis of viral capsid sequences were performed by
DNASTAR Lasergene 10 EN. The complete P1 sequence of the viruses
belonging to the A-Iran-05 strain were aligned and used to con-
struct distance matrices using the Kimura 2-parameter nucleotide
substitution model [6] as implemented in the programme MEGA 6.0
[7]. The aligned P1 sequences were used to construct phylogenetic
trees using MEGA 6.0.
Data analysis: The data analysis was  carried out using Minitab
7.0 software.
3. Results and discussion
The A-Iran-05 viruses were ﬁrst detected in Iran in 2003 [2]
and rapidly spread to neighbouring countries in the Middle East
causing serious problems in Iran in 2005, spreading very quickly to
the neighbouring countries. Subsequently, they produced various
sub-lineages. Most sub-lineages gradually died out, but a few have
persisted. In the last six years, seven sub-lineages (AFG-07, BAR-08,
FAR-09, SIS-10, HER-10, FAR-11 and SIS-12) have been regularly
detected in the region (Table 2). In addition, other sub-lineages like
PAK-09, QAZ-11 and ESF-10 are also occasionally detected (http://
www.wrlfmd.org). In this study, we  have focussed mainly on two
sub-lineages of A-Iran-05, namely SIS-10 and SIS-12 which are cur-
rently circulating in the region. SIS-10 viruses were ﬁrst detected
from cattle in an outbreak in Sistan and Baluchestan province in
Iran in April 2010. Gradually, there was  spread to other provinces
in the west, such as Chaharmahal and Bakhtaran (January 2011),
in central Iran such as Yazd (January 2011), and to the north
as far as Tehran and Qom by January 2011. The lineage contin-
ued to circulate in central Iran (Esphan – October 2011), West
Azerbaijan (November 2011), Qom (July 2012), Tehran (October
2012), Khuzestan and Yazd Province (November 2012) and Alborz
province near Tehran (December 2012 to January 2013), Tehran and
East Azerbaijan Province (January 2013), Ardabil Province (January
2013). SIS-10 viruses spread to Turkey in the later part of 2011 and
have been circulating in Anatolia, Black sea and Marmara regions
(February–March 2013). Viruses of this lineage also spread to Russia
and were detected in Garnukha, Urupsky, and Karachay-Cherkess
in mid-2013. SIS-12 viruses were ﬁrst detected in Zahedan, Sistan
and Baluchestan province in Iran from cattle in June 2012. The
viruses spread to Tehran by October 2012, and were still circulating
ot applicable. The P1 sequences have been submitted to Gene Bank and awaiting
ountry, region Host Date collected Accession No.
osul, Iraq Bovine 1964 Upadhyaya et al. [3]
skisehir, Turkey Bovine 23/06/2006 Upadhyaya et al. [3]
ars, Iran NK 04/11/2009 Upadhyaya et al. [3]
ahedan, Iran Bovine 24/06/2012 This study
om, Iran Bovine 09/07/2012 This study
ehran, Iran Bovine 09/10/2012 This study
ehran, Iran Bovine 25/10/2012 This study
azandaran, Iran Bovine 05/11/2012 This study
azd, Iran Bovine 08/11/2012 This study
sfahan, Iran Bovine 17/11/2012 This study
om, Iran Bovine 18/12/2012 This study
lborz, Iran Bovine 24/12/2012 N/A
avuslar, Turkey Bovine 11/01/2012 This study
ehran, Iran Bovine 01/01/2013 This study
lborz, Iran Bovine 01/01/2013 This study
ast Azerbaijan, Iran Bovine 01/01/2013 This study
rdabil, Iran Bovine 01/01/2013 This study
ehran, Iran Bovine 01/01/2013 N/A
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Table  2
List of sub-lineages of A-Iran-05 viruses detected in the Middle East and neighbouring countries during 2009–2015. AFG: Afghanistan, IRN: Iran, IRQ: Iraq, PAK: Pakistan,
TUR:  Turkey; –: not detected.
Name of the country/sub-lineagesa AFG IRN IRQ PAK TUR
AFG-07b 2009– 11 2009–12 2010 2009–11 2010–11
BAR-08b – 2009–10 2009 2009 2009
FAR-09 – 2009–10, 2013 – 2014–15 –
SIS-10b – 2010–14 2013 – 2011–14
HER-10b 2011 2011–12 – 2012 –
FAR-11 2013 2011, 2013–14 – 2011–15 –
SIS-12 – 2012–13 – 2012–13 –
Other sub-lineages detected in only one country are as follows: ARD-07 in Turkey (2008–2010), ESF-10 in Iran (2010), EZM-07 in Turkey (2008–2009), PAK-09 in Pakistan
(2009), SIN-08 in Pakistan (2008) and QAZ-11 in Iran (2011). AFG-07 was  detected in Bahrain (2009); BAR-08 in Libya (2009), Egypt (2010–2011, 2013), Israel (2009), Lebanon
(2009),  Palestine (2009), and Kuwait (2009); HER-10 in Kazakhstan (2012), Bahrain (2011) and Kyrgyzstan (2011), and SIS-10 in Russia (2013).
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viruses (A/IRN/125/2010 and A/TUR/43/2010) generated in our
F
ba Only sub-lineages detected in more than one country are listed in this table.
b Sub-lineages that were detected in other Asian or African countries.
n Sistan and Baluchestan province, Mazandaran Province, Esphan
rovince, and Qom province in 2012. These viruses were ﬁrst
etected in Pakistan in the Gujrat district in Punjab province in
eptember 2012 and in Islamabad in November 2012.
.1. Serological cross-reaction between recent ﬁeld isolates and
accine strains
The results of the 2D-VNT test using 15 SIS-10/12 viruses from
he ME  are presented in Fig. 1. The three v/s did not cross-react
ith each other indicating they are antigenically distinct. The
ecent ﬁeld viruses isolated in 2012 and 2013 exhibited very poor
ross-reactivity with A22/Iraq BVS (Fig. 1) indicating the v/s is not
uitable for use in the region for FMD  control. Similarly, the viruses
xhibited poor cross-reactivity with A/TUR/2006 BVS except
/IRN/15/2012, A/IRN/25/2012, A/IRN/35/2012 and A/IRN/10/2013
Fig. 1). The reactivity pattern of the recent ﬁeld isolates with
/IRN/78/2009 (belonging to FAR-09 sub-lineage) BVS was  very
imilar to A/TUR/2006 v/s exhibiting moderate cross-reactivity only
ith two isolates (A/IRN/25/2012 and A/IRN/35/2012) employed in
his study (Fig. 1). This indicates that the recent viruses of SIS-10 or
IS-12 sub-lineage, mainly circulating in Iran, Turkey, Pakistan and
ussia may  require a new vaccine to control FMD  outbreaks in the
egion although a highly potent vaccine can protect against viruses
howing low r1-values in some cases [8]. Therefore in vivochallenge
tudies could conﬁrm these ﬁndings.
ig. 1. Antigenic relationship (r1) values of SIS-10 and SIS-12 viruses. The horizontal dot
e  a good match.3.2. Full capsid sequence analysis
The full capsid sequence of 13 SIS-10 and 12 viruses were
generated in this study. The capsid sequence of the two  v/s
and A/IRN/78/2009 were reported in a previous study [3]. The
capsid sequences of the other two isolates (A/IRN/37/2012 and
A/IRN/10/2013) used in this study could not be generated either
because of problems in amplifying the capsid encoding sequences
or having ambiguities at more than 15 nt positions that could not
be resolved even after repeated attempts. All of the sequences
(n = 13) were 2205 nucleotide (nt) long. VP4 was found to be com-
pletely conserved at amino acid (aa) level while VP1 was  the most
variable (data not shown). For phylogenetic analysis the A-Iran-05
virus (2009 onwards) capsid sequences (n = 28) previously gener-
ated in our laboratory [3] or available in GenBank (n = 4) were also
included. Phylogenetic analysis of the capsid sequences revealed
all these viruses belong to the Asia topotype within serotype A
FMDV and grouped with viruses belonging to the A-Iran-05 geno-
type (Fig. 2A). The phylogenetic tree based on VP1 sequence was
broadly in agreement with the tree generated using the full capsid
sequence (data not shown).
The capsid sequence of all the available SIS-10 and -12 viruses
(n = 15) [13 generated in this study along with the two SIS-10previous study] were analysed. VP4 was  found to be completely
conserved at aa level except an aspargine (N) to serine (S) change
at position 61 in A/TUR/43/2010 virus. All these viruses exhibited
ted line indicates the cut-off value of 0.3, above which the vaccine is considered to
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SIS-10 
SIS-12 
AFG-07 
FAR-09 
BAR-08 
ESF-10 
QAZ-11 
A-Iran-96 
A22 
ARD-07 
A/IRN /01 /201 3
A/IRN /24 /201 2
A/IRN /06 /201 3
A/IRN /07 /201 3
A/IRN /32 /201 2
A/IRN /04 /201 3
A/IRN /22 /201 2
A/TUR /43 /201 0
A/TUR /05 /201 2
A/IRN /125 /201 0
A/IRN /30 /201 2
A/IRN /35 /201 2
A/IRN /25 /201 2
A/IRN /15 /201 2
A/IRN /33 /201 2
A/PAK/12 /201 0
A/PAK/24 /201 0
A/KAP/AFG/L1491 /2009 /JF72143 9
A/AFG/34 /201 1
A/IRN /36 /201 1
A/IRN /73 /201 0
A/IRN /73 /200 9
A/TUR /34 /201 0
A/AFG/12 /201 1
A/IRN /78 /200 9
A/PAK/76 /2009 /GU38368 6
A/IRN /63 /200 9
A/PAK/13 /201 0
A/SIN/PAK/L693 /2009 /JF72143 6
A/IRN /06 /200 9
A/IRN /25 /200 9
A/PAK/0420 /09
A/IRN /02 /200 9
A/IRN /37 /200 9
A/TUR /18 /200 9
A/IRN /36 /201 0
A/IRN /09 /201 0
A/KUN /AFG/L1577 /2009 /JF72144 0
A/IRN /45 /201 1
A/BAD/AFG/L2813 /2009 /JF72144 1
A/TUR  07 /200 9
A/TUR /20 /201 0
A/TUR /200 6
A/TUR /04 /200 6
A/TUR /19 /200 6
A/I RQ/108 /02
A/IRN /03 /96
A22/I RQ/24 /64
100
99
100
100
100
100
100
100
100
100
99
73
86
100
100
80
94
97
75
100
97
86
100
77
70
86
0.02
(A)  
Fig. 2. (A) Phylogenetic tree of the SIS-10 and SIS-12 viruses. The sub-lineages deﬁned by WRLFMD on the basis of VP1 sequences are shown in the ﬁgure. The vaccines (existing
and  putative strains) used in this study are underlined. (B) Capsid amino acid substitution in the SIS-10 and SIS-12 viruses compared to A22/IRQ/24/64, A/TUR/2006 and
A/IRN/78/2009 v/s. The residues changed from the v/s are boxed. The grey boxes indicate substitutions in ten out of 15 viruses. The residue positions potentially antigenically
important for the antigenic drift from A/TUR/2006 v/s are shown in bold and underlined. (C and D) 3-D structure of Type A10 protomer showing capsid amino acid residues
identiﬁed in this study; VP1 96 (red), VP2 191 (green), VP3 65 (blue). Residues identiﬁed in 10 out of 15 viruses: VP1 – magenta, VP3 – yellow. Residues of potential antigenic
signiﬁcance in case of A/TUR/2006 v/s: VP1 – raspberry, VP2 – orange, VP3 – cyan, VP1 141 not on structure. (C) – cartoon, (D) – external surface. (E) A10 structure with two
protomers showing proximity of C-terminal residues of VP1 in an adjacent protomer (mesh). Colour code is same as in (D). Red circles indicate antigenic site 1 residues (VP1
198,  201 and 204) of an adjacent protomer. The white circles indicate the three antigenic sites.
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136      145       155       165       175
....|....|....|....|....|....|....|....|
A22/IRQ/24/64 YSAG GTGRRGDLGPLAARVAAQLPASFNFGAIQATTIHE L
A/TUR/2006 ..TT.N.......S..........S.......R...... .
A/IRN/78/2009 ..TT.GS......S..........S.......R...... .
A/IRN/125/2010 ..TT.G..................S..........N....
A/TUR/43/2010 ..TTVG.......S..........S.......R..S... .
A/IRN/15/2012 ..TT.G.......S..........S.......R...... .
A/IRN/22/2012 ..TT.G D......S.......H..S.......K..N... .
A/IRN/24/2012 ..TT.GD......S.......H..S.......K..N... .
A/IRN/25/2012 ..TT.G.......S..........S.......R...... .
A/IRN/30/2012 ..TT.GD......S.......H..S.......K..N... .
A/IRN/32/2012 ..TT.G.......S..........S..... ..R...... .
A/IRN/33/2012 ..TT.G.......S..........S.......R...... .
A/IRN/35/2012 ..TT.G.......S..........S.......R...... .
A/TUR/05/2012 ...T.G..................S.......R..N... .
A/IRN/01/2013 ..TT.GD......S.......H..S.......K..N... .
A/IRN/04/2013 ..TT.GD......S.......H..S.......K..N... .
A/IRN/06/2013 ..TT.GD......S.......H..S.......K..N... .
A/IRN/07/2013 ..TT.GD......S.......H..S.......K..N... .
VP2
121      130       140
....|....|....|....|....|
A22/IRQ/24/64 LLVAMVPEWKEF TPREKYQLTLFP H
A/TUR/2006 ..........K............. .
A/IRN/78/2009 .............L.......... .
A/IRN/125/2010 .............T.......... .
A/TUR/43/2010 .............T.......... .
A/IRN/15/2012 .............L.......... .
A/IRN/22/2012 .............T.......... .
A/IRN/24/2012 .............T.......... .
A/IRN/25/2012 .............L.......... .
A/IRN/30/2012 .............T.......... .
A/IRN/32/2012 .............L......... ..
A/IRN/33/2012 .............L...H...... .
A/IRN/35/2012 .............L.......... .
A/TUR/05/2012 .............T.......... .
A/IRN/01/2013 .............T.......... .
A/IRN/04/2013 .............T.......... .
A/IRN/06/2013 .............T....... ... .
A/IRN/07/2013 .............T.......... .
(B)
VP1
21       30        40
....|....|....|....|
A22/IRQ/24/64 ETQVQR RQHTDVTFIMDRF V
A/TUR/2006 ...A........G...... .
A/IRN/78/2009 ...D...H....G...... .
A/IRN/125/2010 ...A...H....G...... .
A/TUR/43/2010 ...A...H....G.......
A/IRN/15/2012 ...A...H....G...... .
A/IRN/22/2012 .......H....G...... .
A/IRN/24/2012 .......H....G...... .
A/IRN/25/2012 ...A...H.. ..G...... .
A/IRN/30/2012 .......H....G...... .
A/IRN/32/2012 ...A...H....G...... .
A/IRN/33/2012 ...A...H....G...... .
A/IRN/35/2012 ...A...H....G...... .
A/TUR/05/2012 ...A...H....S...... .
A/IRN/01/2013 .......H....G...... .
A/IRN/04/2013 .......H....G...... .
A/IRN/06/2013 .......H....G...... .
A/IRN/07/2013 .......H....G...... .
81 90 100
....|....|....|....|....|
A22/IRQ/24/64 RHDGNLTWVPNGAPEAALSNTGNP T
A/TUR/2006 ..............VE..A..S.. .
A/IRN/78/2009 ...............E..V..S.. .
A/IRN/125/2010 ..E.H.........VG..V..S.. .
A/TUR/43/2010 ..E.H.........VG..V..S.. .
A/IRN/15/2012 ...............G..A..S.. .
A/IRN/22/2012 ..E.H.........VG..V..S.. .
A/IRN/24/2012 ..E.H.........VG..V..S.. .
A/IRN/25/2012 ...............G..A..S.. .
A/IRN/30/2012 ..E.H.........VG..V..S.. .
A/IRN/32/2012 ...............G..A..S.. .
A/IRN/33/2012 ...............G..A..S.. .
A/IRN/35/2012 ...............G..A..S.. .
A/TUR/05/2012 ..E.H.........VG..V..S.. .
A/IRN/01/2013 ..E.H.........VG..V..S.. .
A/IRN/04/2013 ..E.H.........VG..V..S.. .
A/IRN/06/2013 ..E.H.........VG..V..S.. .
(Cont
s
c
(
a
c
a
m
(
3
A
s
a
p
t
a
d
eA/IRN/07/2013 ..E.H.........VG..V..S.. .
Fig. 2. 
igniﬁcantly higher variation at nt level when compared to A22/Iraq
apsid sequence than the other two vaccines used in this study
14.0–15.4% variation from A22/Iraq compared to 5.0–7.4% vari-
tion from A/TUR/2006 v/s). The nt variation was  5.0–7.0% when
ompared to the A/IRN/78/2009 v/s capsid sequence. The capsid
mino acid sequences were also analysed and the aa variation was
uch higher compared to A22/Iraq (6.4–7.1%) than to A/TUR/2006
3.0–4.1%) and A/IRN/78/2009 (3.0–4.4%).
.3. Comparison between A22/Iraq, A/TUR/2006 and
/IRN/78/2009 v/s, and SIS-10 and -12 ﬁeld isolates
In vitro testing of viruses belonging to the SIS-10 and SIS-12
ub-lineages with either A22/Iraq, A/TUR/2006 or A/IRN/78/2009
ntisera generated low r1-values indicating lower expectancy of
rotection. The capsid aa sequences of these viruses along with
wo SIS-10 viruses reported in our previous study (see above) were
nalysed further to understand the molecular basis of the antigenic
rift. The aa sequence of VP4 was found to be completely conserved
xcept a single aa change in one virus (isolated in 2010) whereasinued )
multiple changes were observed in the other three viral proteins.
As most of these SIS-10 and SIS-12 viruses exhibited poor cross-
reactivity with the three BVS used in this study, we speciﬁcally
looked for amino acid residues in the capsid sequence of the ﬁeld
isolates which were different from those of the vaccine strains.
A total of three aa residues (VP1-96, VP2-191 and VP3-65) were
identiﬁed; one each in the three surface-exposed capsid proteins,
VP1-3 (Fig. 2B). All these residues are surface exposed (Fig. 2D)
and could explain the inability of the antisera to cross-react with
the ﬁeld isolates, and are probably the sites prone to change to
help the virus escape immune pressure. Out of these, VP2-191 has
been reported to be part of a neutralising epitope (antigenic site-2)
both in serotype O and A FMDV [9,10]. Further, epitopes involving
antigenic site 2 have been reported to be dominant within poly-
clonal responses of vaccinated animals [11]. Similarly, VP3-65 was
identiﬁed in our previous study in viruses belonging to the BAR-08
sub-lineage [3]. Further, several residues in VP3 58–71 (antigenic
site-4) have been reported to contribute to an epitope in serotype A
either by monoclonal antibody (mAb) neutralisation resistant (mar)
mutant studies [12] or by using structure-based epitope prediction
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181      190       200
....|....|....|....|....|
A22/IRQ/24/64 VMVVSPLTTNTVSAGQIKVYANIA P
A/TUR/2006 .........SSIG.S......... .
A/IRN/78/2009 .........SSIG.S......... .
A/IRN/125/2010 ..........NIG.S......... .
A/TUR/43/2010 ..........NIG.S......... .
A/IRN/15/2012 .........SDIG.P......... .
A/IRN/22/2012 .........SNIG.S..........
A/IRN/24/2012 .........SNIG.S..........
A/IRN/25/2012 .........SDIG.P..........
A/IRN/30/2012 .........SNIG.S......... .
A/IRN/32/2012 .........SDIG.P..........
A/IRN/33/2012 .........SDIG.P......... .
A/IRN/35/2012 .........SDIG.P......... .
A/TUR/05/2012 ..........NIG.P......... .
A/IRN/01/2013 .........SNIG.S......... .
A/IRN/04/2013 .........SNIG.S..........
A/IRN/06/2013 .........SNIG.S......... .
A/IRN/07/2013 .........SNIG.S......... .
VP3
61       70        80
....|....|....|....|
A22/IRQ/24/64 KPYVVTRTDEQRLLAKFDV S
A/TUR/2006 .........D......... .
A/IRN/78/2009 ................... .
A/IRN/125/2010 ....E....A......... .
A/TUR/43/2010 ....E....A......... .
A/IRN/15/2012 ....E.G.G......R... .
A/IRN/22/2012 ....E....A......... .
A/IRN/24/2012 ....E....A......... .
A/IRN/25/2012 ....E.G.G......R... .
A/IRN/30/2012 ....E....A......... .
A/IRN/32/2012 ....E.G.G......R... .
A/IRN/33/2012 ....E.G.G.. ....R... .
A/IRN/35/2012 ....E.G.G......R... .
A/TUR/05/2012 ....E..A.A......... .
A/IRN/01/2013 ....E....A......... .
A/IRN/04/2013 ....E....A......... .
A/IRN/06/2013 ....E....A......... .
166      175       185
....|....|....|....|
A22/IRQ/24/64 ADYAYTASDVAETTNVQGWV
A/TUR/2006 ................... .
A/IRN/78/2009 ................... .
A/IRN/125/2010 .........E......... .
A/TUR/43/2010 .........E..........
A/IRN/15/2012 ................... .
A/IRN/22/2012 .........E..........
A/IRN/24/2012 .........E......... .
A/IRN/25/2012 ....................
A/IRN/30/2012 .........E......... .
A/IRN/32/2012 ........... ..V..... .
A/IRN/33/2012 ................... .
A/IRN/35/2012 .............V..... .
A/TUR/05/2012 .........E......... .
A/IRN/01/2013 .........E......... .
A/IRN/04/2013 .........E......... .
A/IRN/06/2013 .........E......... .
A/IRN/07/2013 .........E..A...... .
206      215
....|....|....|.
A22/IRQ/24/64 AGKDFELRLPIDP RSQ
A/TUR/2006 ..............T .
A/IRN/78/2009 ..............A .
A/IRN/125/2010 ..............A .
A/TUR/43/2010 ..............A .
A/IRN/15/2012 ..............A .
A/IRN/22/2012 ..............A .
A/IRN/24/2012 ..............A .
A/IRN/25/2012 ..............A .
A/IRN/30/2012 ..............A .
A/IRN/32/2012 ..............A .
A/IRN/33/2012 ..............A .
A/IRN/35/2012 ..............A .
A/TUR/05/2012 ..............A .
A/IRN/01/2013 ..............A .
A/IRN/04/2013 ..............A .
A/IRN/06/2013 ..............A .
A/IRN/07/2013 ..............A .
(Cont
s
a
t
a
e
(
w
m
i
i
c
b
o
V
r
b
t
r
r
t
t
t
bA/IRN/07/2013 ....E....A......... .
Fig. 2. 
oftwares [13]. The change in VP1-96 has not been associated with
ntigenic signiﬁcance, however, it is located in close proximity to
he C-terminus of VP1 (of an adjacent protomer) that constitutes
ntigenic site 1 (Fig. 2E), and could be part of previously identiﬁed
pitopes.
In addition, ﬁve capsid amino acid substitutions, two in VP3
positions 70 and 175) and three in VP1 (positions 83, 85 and 171),
ere observed in ten out of 15 viruses (boxed grey in Fig. 2B) which
ay  have some impact on the antigenic nature of the virus. Interest-
ngly, these changes at ﬁve different positions were only observed
n SIS-10 viruses. Out of these, VP1-83 was identiﬁed as a likely
ontributor to antigenic change in our previous study of viruses
elonging to the BAR-08 sub-lineage [3] and was reported previ-
usly as an epitope in A12 virus by mar  mutant studies [14]. Though
P1-171 has never been reported to be of antigenic signiﬁcance,
esidues 169 and 173 located close to residue 171 were reported to
e epitopes in A10 and A12 viruses by mar  mutant studies, respec-
ively [12,14]. The two residues in VP3, positions 70 and 175 were
eported as epitopes in serotype A viruses, A10 and A12 viruses,
espectively by mar  mutant studies [12,14]. Thus, it appears that
he residues within or close to neutralising antigenic sites are ﬁrst
argeted by the immune pressure in FMDV in an attempt to adapt
o the changing environment.
Our previous study [3] identiﬁed eight aa residues as responsi-
le for the antigenic drift of the A-Iran-05 viruses from A/TUR/2006inued )
v/s, out of which four (VP1-28, 141; VP2-134 and VP3-220) were
also implicated in this study (residues in bold and positions under-
lined in Fig. 2B–D). Of these, VP2-134 has been reported to inﬂuence
binding of antigenic site 2 mAbs in serotype O viruses [15] and
VP1-141 has been reported to be critical in serotype A mar  mutant
studies involving antigenic site 1 [16].
3.4. Serological cross-reaction between recent ﬁeld isolates and
putative vaccine strain
The poor cross-reactivity of the recent ﬁeld viruses isolated in
2012 and 2013 with two  existing vaccine strains and one putative
vaccine strain strongly suggests that these v/s are not suitable for
use in the region for FMD  control. Therefore, development of new
vaccine strains should be a priority to help control the serotype A
outbreaks in this region. As a ﬁrst step, we  selected a more recent
isolate from SIS-10 sub-lineage, and raised antisera in cattle. The
pooled antisera (from 5 cattle) were used in serological assays to
assess their suitability for development as a new v/s. All the viruses
employed in this study exhibited a good match with the new anti-
sera (Fig. 3) indicating its potential as a candidate v/s, subject to
fulﬁlment of other criteria, such as suitable production and stability
characteristics, and in vivoevaluation in the target host.
In summary, analysis of the genetic and antigenic data of the
SIS-10 and -12 viruses revealed substitutions in antigenic sites,
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specially site 1, 2 and 4 that either individually or together could
nderpin the antigenic drift of these type A viruses. Mutagenesis
tudies involving a cDNA clone could help to conﬁrm these observa-
ions. The high rate of evolution in FMDV results in the emergence of
ew sub-lineages of serotype A viruses in the Middle East, requiring
evelopment of a new v/s every 5–10 years. Therefore, close mon-
toring of the outbreak strains in this area is essential to enable
ppropriate vaccines to be selected, and the need to develop a new
/s should be identiﬁed in a timely fashion to prevent future out-
reaks. The results from this study highlight the continuing need
ig. 3. Antigenic relationship (r1) values of SIS-10 and SIS-12 viruses with
/IRN/07/2013 strain. The horizontal dotted line indicates the cut-off value of 0.3,
bove which the vaccine is considered to be a good match.nued. )
for comprehensive surveillance and the urgency for development
of a new serotype A vaccine for use in control programmes in this
region.
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